Physician profile
Byron Mui
NPI 1891972121
$4,328.74
in general payments reported to CMS, 2019-2025
33 companies · $352 in 2025
The $352 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $105 · 2021: $1,111 · 2022: $1,138 · 2023: $878 · 2024: $744 · 2025: $352.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,889 · Education: $84.94.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,889.32 |
| Education | $84.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $885.91 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $589.39 | 2021-2025 | Mounjaro, Zepbound, Trulicity |
| Corcept Therapeutics | $487.81 | 2022-2025 | Korlym |
| Astrazeneca Pharmaceuticals LP | $233.03 | 2021-2024 | Farxiga |
| Glaxosmithkline, LLC. | $222.19 | 2021-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Merck Sharp & Dohme LLC | $221.79 | 2020-2023 | Verquvo, Steglatro, Belsomra |
| Astellas Pharma US INC | $217.93 | 2024-2025 | Veozah, Cresemba |
| Boehringer Ingelheim Pharmaceuticals, INC. | $217.85 | 2021-2023 | Jardiance, Synjardy |
| Abbvie INC. | $161.89 | 2020-2024 | |
| Abbott Laboratories | $122.71 | 2022-2025 | Freestyle Libre 3 |
| Radius Health, INC. | $108.35 | 2020-2023 | Tymlos |
| Shield Therapeutics INC | $106.05 | 2023-2025 | Accrufer |
| Insulet Corporation | $74.10 | 2021 | |
| Dexcom, INC. | $70.68 | 2021-2024 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $69.29 | 2021-2023 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mannkind Corporation | $51.30 | 2021-2022 | |
| Cequr Corporation | $45.78 | 2023-2024 | Cequr Simplicity |
| Antares Pharma, INC. | $43.87 | 2023-2024 | Xyosted, Nocdurna, Tlando |
| Zealand Pharma US, INC. | $40.07 | 2022 | |
| Idorsia Pharmaceuticals US INC | $37.67 | 2023 | Quviviq |
| Recordati_rare_diseases_inc. | $37.39 | 2025 | Isturisa |
| Amarin Pharma, INC. | $36.69 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $35.00 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $31.38 | 2021-2022 | |
| Amgen INC. | $26.51 | 2021 | |
| Abiomed | $24.75 | 2025 | |
| Exact Sciences Corporation | $23.15 | 2024 | Cologuard Collection Kit |
| Kyowa Kirin, INC. | $22.29 | 2023 | Crysvita |
| Baxter Healthcare | $21.29 | 2024 | Hillrom - Vest System Model 105 Home Care |
| Biohaven Pharmaceuticals, INC. | $18.63 | 2021 | |
| Becton, Dickinson and Company | $15.79 | 2022 | |
| Amryt Pharma Holdings LTD | $14.19 | 2023 | Mycapssa |
| Arbor Pharmaceuticals, INC. | $14.02 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Byron Mui listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.